Giulia Ferrannini

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

21st April 2023: PhD thesis defence. Title: “Dysglycaemia and cardiovascular disease. Aspects on screening, management and prognosis.” 2020 - 2023: PhD, Cardiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 2022 - current: Consultant in internal medicine, VO Internmedicin, Södertälje hospital. 2021 - 2022: Physician at the Geriatric Unit, Löwenströmska hospital. 2014 – 2019: Residency in Internal Medicine at the University of Torino, Italy. 2007 – 2013: Medical Degree, University of Modena and Reggio Emilia, Italy.

Artiklar

Article: ESC HEART FAILURE. 2024;11(2):759-771

N-terminal pro-B-type natriuretic peptide concentrations, testing and associations with worsening heart failure events.

Ferrannini G; Benson L; Lautsch D; Dahlström U; Lund LH; Savarese G; Carrero JJ
Article: BMJ OPEN. 2024;14(3):e078983

Universal screening for early detection of chronic autoimmune, metabolic and cardiovascular diseases in the general population using capillary blood (UNISCREEN): low-risk interventional, single-centre, pilot study protocol.

Merolla A; De Lorenzo R; Ferrannini G; Renzi C; Ulivi F; Bazzigaluppi E; Lampasona V; Bosi E
Article: DIABETES CARE. 2024;47(2):S493

High Mannose Correlates With Surrogate Indexes of Insulin Resistance and Is Associated With an Increased Risk of Cardiovascular Events Independently of Glycemic Status and Traditional Risk Factors.

Fortin E; Campi B; Ferrannini E; Mari A; Mellbin LG; Norhammar A; Näsman P; Rydén L; Saba A; Ferrannini G
Article: CARDIOVASCULAR DIABETOLOGY. 2024;23(1):25

Sex differences in the association between insulin resistance and non-fatal myocardial infarction across glycaemic states.

Riccio A; Fortin E; Mellbin L; Norhammar A; Näsman P; Rydén L; Sesti G; Ferrannini G
Article: SCANDINAVIAN CARDIOVASCULAR JOURNAL. 2023;57(1):2166101

Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial.

Ferrannini G; Maldonado JM; Raha S; Rao-Melacini P; Khatun R; Atisso C; Shurzinske L; Gerstein HC; Rydén L; Bethel MA
Journal article: EUROPEAN HEART JOURNAL. 2023;44:ehad655.1443

High mannose correlates with surrogate indexes of insulin resistance and predicts cardiovascular events independently of glycaemic status and traditional risk factors

Fortin E; Campi B; Ferrannini E; Mari A; Mellbin L; Norhammar A; Nasman P; Ryden L; Saba A; Ferrannini G
Journal article: EUROPEAN HEART JOURNAL. 2023;44:ehad655.974

The management of patients with heart failure in Sweden: a survey conducted among physicians in Sweden

Ferrannini G; Biber ME; Abdi S; Stalberg M; Lund LH; Savarese G
Journal article: EUROPEAN HEART JOURNAL. 2023;44:ehad655.2535

Association between body mass index and outcomes in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry

Ferrannini G; Rodolico D; Amario DD; Dahlstrom U; Lund LH; Savarese G
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2023;25(9):1648-1658

Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.

Stolfo D; Lund LH; Benson L; Lindberg F; Ferrannini G; Dahlström U; Sinagra G; Rosano GMC; Savarese G
Article: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):208

Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia : Experiences from the randomized, controlled SOCOGAMI trial.

Fortin E; Lundin M; Mellbin L; Norhammar A; Näsman P; Smetana S; Sörensson P; Ferrannini E; Rydén L; Ferrannini G
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2023;25(8):1418-1428

Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry.

Nguyen NV; Lindberg F; Benson L; Ferrannini G; Imbalzano E; Mol PGM; Dahlström U; Rosano GMC; Ezekowitz J; Butler J; Lund LH; Savarese G
Article: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):100

Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE.

Ferrannini G; Pollock C; Natali A; Yavin Y; Mahaffey KW; Ferrannini E
Article: RHEUMATOLOGY. 2023;62(3):1187-1196

Antiphospholipid antibodies in patients with calcific aortic valve stenosis.

Plunde O; Svenungsson E; Ferrannini G; Franco-Cereceda A; Bäck M
Article: SCANDINAVIAN CARDIOVASCULAR JOURNAL. 2022;56(1):337-342

Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANK.

Ferrannini G; Almosawi M; Buhlin K; De Faire U; Kjellström B; Klinge B; Nygren Å; Näsman P; Svenungsson E; Rydén L; Norhammar A
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2022;9(1):10-17

Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis.

Ferrannini G; Lund LH; Benson L; Rizzo M; Almahmeed W; Rosano GMC; Savarese G; Cosentino F
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2022;193:110141

SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI).

Lundin M; Ferrannini G; Mellbin L; Johansson I; Norhammar A; Näsman P; Shahim B; Smetana S; Venkateshvaran A; Wang A; Sörensson P; Rydén L
Article: EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING. 2022;21(7):717-723

Gender differences in lifestyle management among coronary patients and the association with education and age: results from the ESC EORP EUROASPIRE V registry.

Vynckier P; Ferrannini G; Kotseva K; Gevaert S; De Bacquer D; De Smedt D
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):195

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study.

Fortin E; Ferrannini G; Campi B; Mellbin L; Norhammar A; Näsman P; Saba A; Ferrannini E; Rydén L
Article: DIABETES CARE. 2022;45(9):2111-2117

Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V Population.

Ferrannini G; De Bacquer D; Erlund I; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Schnell O; Tuomilehto J; Vihervaara T; Wood D; Rydén L
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):129

Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort.

Meziani S; Ferrannini G; Bjerre M; Hansen TK; Ritsinger V; Norhammar A; Gyberg V; Näsman P; Rydén L; Mellbin LG
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):127

Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program.

Ferrannini G; Rosenthal N; Hansen MK; Ferrannini E
Article: JOURNAL OF CARDIAC FAILURE. 2022;28(7):1050-1062

Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.

Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2022;29(2):344-351

Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry.

Vynckier P; Ferrannini G; Rydén L; Jankowski P; De Backer T; Gevaert S; De Bacquer D; De Smedt D; EUROASPIRE V Investigators group
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2022;183:109156

Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test: Validation of a new screening algorithm in patients with coronary artery disease from the ESC-EORP EUROASPIRE V registry.

Ferrannini G; De Bacquer D; Gyberg V; De Backer G; Kotseva K; Mellbin LG; Risebrink R; Tuomilehto J; Wood D; Rydén L
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2022;346:86-92

Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance.

Ferrannini E; Marx N; Andreini D; Campi B; Saba A; Gorini M; Ferrannini G; Milzi A; Magnoni M; Maseri A; Maggioni AP; Burgmaier M; CAPIRE investigators
Journal article: EUROPEAN HEART JOURNAL. 2021;42(Supplement_1):ehab724.1106

Long term outcome after a first myocardial infarction

Almosawi M; Ferrannini G; Buhlin K; Gustafsson A; Kjellstrom B; Klinge B; Nygren Å; Nasman P; Svenungsson E; Ryden L; Norhammar A
Journal article: EUROPEAN HEART JOURNAL. 2021;42(Supplement_1):ehab724.1120

Periodontitis and cardiovascular outcome – a prospective follow-up of the PAROKRANK cohort

Ferrannini G; Norhammar A; Almosawi M; Kjellstrom B; Buhlin K; De Faire U; Gustafsson A; Nygren LA; Nasman P; Lindahl B; Naslund U; Svenungsson E; Klinge B; Ryden L
Article: CARDIOVASCULAR DRUGS AND THERAPY. 2021;35(4):801-808

Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry.

Vynckier P; Ferrannini G; Rydén L; Tokgözoğlu L; Bruthans J; Kotseva K; Wood D; De Backer T; Gevaert S; De Bacquer D; De Smedt D; EUROASPIRE V Investigators group
Article: EUROPEAN HEART JOURNAL. 2021;42(26):2565-2573

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.

Ferrannini G; Gerstein H; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probstfield J; Riddle MC; Shaw JE; Avezum A; Basile JN; Cushman WC; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pais P; Pīrāgs V; Pogosova N; Raubenheimer PJ; Sheu WH-H; Rydén L
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2021;23(6):1012-1022

Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.

Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2021;175:108796

Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.

Ferrannini G; Savarese G; Rydén L
Article: CARDIOVASCULAR DIABETOLOGY. 2021;20(1):38

Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys.

Ferrannini G; De Bacquer D; Vynckier P; De Backer G; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Tuomilehto J; Wood D; Rydén L; EUROASPIRE IV & V Investigators
Article: FRONTIERS IN CARDIOVASCULAR MEDICINE. 2021;8:790289

Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans.

Ferrannini E; Manca ML; Ferrannini G; Andreotti F; Andreini D; Latini R; Magnoni M; Williams SA; Maseri A; Maggioni AP
Article: DIABETES CARE. 2020;43(9):2001-2009

Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management.

Ferrannini G; Norhammar A; Gyberg V; Mellbin L; Rydén L
Article: DIABETES CARE. 2020;43(4):726-733

Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V.

Ferrannini G; De Bacquer D; De Backer G; Kotseva K; Mellbin L; Wood D; Rydén L; EUROASPIRE V collaborators
Article: DIABETES CARE. 2020;43(4):843-851

Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study.

Ferrannini G; Manca ML; Magnoni M; Andreotti F; Andreini D; Latini R; Maseri A; Maggioni AP; Ostroff RM; Williams SA; Ferrannini E
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2020;17(3):1479164120922123-147916412092212

Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?

Ferrannini G; Svenungsson E; Kjellström B; Elvin K; Grosso G; Näsman P; Rydén L; Norhammar A
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2019;26(2_suppl):81-91

Risk factor reduction in type 2 diabetes demands a multifactorial approach.

Rydén L; Ferrannini G; Mellbin L
Article: ENDOCRINE. 2017;55(3):885-898

Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients.

Diazzi C; Brigante G; Ferrannini G; Ansaloni A; Zirilli L; De Santis MC; Zona S; Guaraldi G; Rochira V
Article: MOLECULAR METABOLISM. 2016;5(10):948-958

Genetic backgrounds determine brown remodeling of white fat in rodents.

Ferrannini G; Namwanje M; Fang B; Damle M; Li D; Liu Q; Lazar MA; Qiang L
Article: DIABETES CARE. 2015;38(9):1730-1735

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

Ferrannini G; Hach T; Crowe S; Sanghvi A; Hall KD; Ferrannini E
Visa fler

Alla övriga publikationer

Editorial comment: EUROPEAN HEART JOURNAL. 2023;44(28):2557-2559

Risk prediction in patients with diabetes: is SCORE 2D the perfect solution?

Rydén L; Ferrannini G; Standl E
Corrigendum: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2023;9(3):293

Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis.
KI thesis / dissertation: 2023

Dysglycaemia and cardiovascular disease. Aspects on screening, management, and prognosis

Ferrannini, Giulia
Conference publication: DIABETOLOGIA. 2023;66(SUPPL 1):S247

Sex differences in the association between insulin resistance indexes and myocardial infarction in individuals with different glycaemic states

Riccio A; Mellbin L; Norhammar A; Nasman P; Ryden L; Sesti G; Ferrannini G
Conference publication: DIABETOLOGIA. 2023;66(SUPPL 1):S243-S244

Empagliflozin improves insulin sensitivity in patients with a recent coronary syndrome and newly detected dysglycaemia

Ferrannini G; Fortin E; Mellbin L; Norhammar A; Nasman P; Smetana S; Ferrannini E; Ryden L
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2023;25:21

Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE

Ferrannini GG; Pollock C; Natali A; Yavin Y; Mahaffey KW; Ferrannini E
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2023;25:135-136

N-terminal pro-B-type natriuretic peptide concentrations, testing and associations with outcomes: an analysis of the swedish heart failure registry and the stockholm creatinine measurements cohorts

Ferrannini GG; Savarese G; Benson L; Lautsch D; Dahlstrom U; Lund L; Carrero JJ
Review: HEART FAILURE CLINICS. 2022;18(4):551-559

SGLT2 Inhibitors in Type 2 Diabetes Mellitus.

Ferrannini G; Savarese G; Cosentino F
Editorial comment: DIABETES CARE. 2022;45(10):e146-e147

Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis.

Ferrannini G; Mellbin LG; Kirabo F; Ramasundarahettige C; Gerstein HC; Rydén L
Editorial comment: EUROPEAN CARDIOLOGY. 2022;17:e12

New Trial Evidence on Heart Failure: Highlights from the European Society of Cardiology Congress 2021.

Ferrannini G; Savarese G
Editorial comment: LANCET DIABETES & ENDOCRINOLOGY. 2022;10(1):3-5

Is the impact of add on heart failure therapy influenced by background therapy?

Rydén L; Ferrannini G
Conference publication: EUROPEAN HEART JOURNAL. 2022;43:2400

Does dulaglutide impact a composite outcome reflecting atherosclerosis? A post-hoc analysis of the REWIND trial

Ferrannini G; Mellbin L; Kirabo F; Ramasundarahettige C; Herstein HG; Ryden L
Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S412-S413

Plasma mannose and a first myocardial infarction: associations according to glycaemic state

Fortin E; Ferrannini G; Campi B; Mellbin L; Norhammar A; Nasman P; Saba A; Ferrannini E; Ryden L
Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S443

Measures of insulin resistance as a screening tool for dysglycaemia in patients with coronary artery disease: a report from the EUROASPIRE V population

Ferrannini G; De Bacquer D; Erlund I; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Schnell O; Tuomilehto J; Vihervaara T; Wood D; Ryden L
Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S413

Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program

Ferrannini E; Ferrannini G; Rosenthal N; Hansen MK
Editorial comment: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(3):e4

SGLT2i: new perspectives in diabetes and kidney disease.

Ferrannini G; Cosentino F
Editorial comment: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2021;28(1):18-21

Is cardioprotection with GLP-1 receptor agonists a class effect?

Rydén L; Ferrannini G; Mellbin L
Conference publication: DIABETOLOGIA. 2021;64(SUPPL 1):4-5

Gender differences in cardiovascular risk, treatment, and outcomes: a post-hoc analysis from the REWIND trial

Ferrannini G; Maldonado JM; Raha S; Rao-Melacini P; Khatun R; Atisso C; Shurzinske L; Gerstein H; Ryden L; Bethel MA
Conference publication: EUROPEAN HEART JOURNAL. 2021;42:1106

Long term outcome after a first myocardial infarction

Almosawi M; Ferrannini G; Buhlin K; Gustafsson A; Kjellstrom B; Klinge B; Nygren A; Nasman P; Svenungsson E; Ryden L; Norhammar A
Conference publication: EUROPEAN HEART JOURNAL. 2021;42:1120

Periodontitis and cardiovascular outcome - a prospective follow-up of the PAROKRANK cohort

Ferrannini G; Norhammar A; Almosawi M; Kjellstrom B; Buhlin K; De Faire U; Gustafsson A; Nygren LA; Nasman P; Lindahl B; Naslund U; Svenungsson E; Klinge B; Ryden L
Editorial comment: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2020;6(6):341-342

Cardiorenal protection of sodium-glucose cotransporter 2 inhibitors beyond diabetes: news from the European Society of Cardiology Congress 2020.

Ferrannini G
Conference publication: EUROPEAN HEART JOURNAL. 2020;41:3353

Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial

Ferrannini G; Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probslfield J; Riddles MC; Shaw JE; Ryden L
Conference publication: DIABETOLOGIA. 2020;63(SUPPL 1):S282

Cardio protection with dulaglutide is not depending on baseline therapy with metformin: a subgroup analysis of the REWIND trial

Ferrannini G; Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probstfield J; Riddle MC; Shaw JE; Ryden L
Conference publication: LUPUS. 2019;28:42

Dysglycaemic patients with antiphospholipid antibodies IgG: a neglected group at high cardiovascular risk?

Ferrannini G; Svenungsson E; Kjellstrom B; Elvin K; Grosso G; Nasman P; Ryden L; Norhammar A
Conference publication: LUPUS. 2019;28:39-40

Domain specific anti-β2GPI antibodies in patients with First Myocardial Infarction

Sippl N; Grosso G; Ferrannini G; de Faire U; Lindahl B; Nasman P; Norhammar A; Ryden L; Svenungsson E; Amara K
Review: CLINICAL SCIENCE. 2018;132(18):2003-2012

Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data.

Ferrannini G; Rydén L
Conference publication: DIABETOLOGIA. 2014;57:S8

Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition

Ferrannini G; Hach T; Crowe S; Ferrannini E
Conference publication: ENDOCRINE REVIEWS. 2014;35(3)

GH Deficiency in HIV-Infected Patients Compared to Hypopituitary Patients

Brigante G; Diazzi C; Ferrannini G; De Vincentis S; Guaraldi G; Ansaloni A; Simoni M; Rochira V
Visa fler

Anställningar

Postdoktor, Fysiologi och farmakologi, Karolinska Institutet, 2024-2025
Postdoktor, Medicin, Solna, Karolinska Institutet, 2024-2024
Postdoktor, Medicin, Solna, Karolinska Institutet, 2024-2024
Postdoktor, Medicin, Solna, Karolinska Institutet, 2024-2024

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Nyheter från KI

Kalenderhändelser från KI